Cytek Biosciences up 6% on $50M buyback approval
- Cytek Biosciences (NASDAQ:CTKB) Board of Directors has approved the repurchase of up to an aggregate of $50M of its stock.
- The repurchase program will continue until the end of the fiscal year unless extended or shortened by the Board of Directors.
- The amount and timing of any repurchases made under the repurchase program will depend on a variety of factors, including available liquidity, cash flow and market conditions.
- The stock price up 6.3% during pre-market.